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EDITORIAL
A word of caution regarding proposed benefits of
albumin from ALBIOS: a dose of healthy skepticism
Alexander H Flannery1,2*, Sean P Kane3 and Angel O Coz-Yataco4
See related letter by Caironi and Gattinoni, http://ccforum.com/content/18/5/510
Introduction
The recently published Albumin Italian Outcome Sepsis
(ALBIOS) study was a prospective, open-label, multi-
center, controlled trial of 1,818 patients with severe sepsis
or septic shock [1]. Patients were randomized to receive
either albumin 20% daily to maintain a serum albumin
level ≥3 g/dl or no albumin replacement. No differences
were detected in overall 28-day mortality, 90-day mortality,
or a number of other secondary outcomes. However, three
potential benefits of albumin were proposed that deserve
further scrutiny.
Caution in interpreting the subgroup analysis
A post hoc, exploratory analysis of patients with septic
shock suggested a reduced relative risk of mortality at
90 days in the albumin group (relative risk 0.87; 95%
confidence interval 0.77 to 0.99). While preserved when
adjusting for imbalances in baseline characteristics,
statistical significance was lost when adjusted for clinically
relevant variables (relative risk 0.88; 95% confidence
interval 0.77 to 1.01). More importantly, one must consider
why a subgroup analysis of 90-day mortality, a secondary
outcome, was performed rather than a subgroup analysis
of the primary outcome, 28-day mortality. After all, 28-day
mortality was the outcome reported in the hypothesis-
generating Saline versus Albumin Fluid Evaluation study
subgroup analysis of patients with severe sepsis [2]. The
28-day mortality comparison in the subgroup of patients
with septic shock was presented by the ALBIOS study
group at professional meetings, although not in the
manuscript or appendix, and indeed is not significant
(relative risk 0.95; 95% confidence interval 0.81 to 1.10)
[3]. It is clinically difficult to explain a mortality benefit
with albumin that only emerges beyond 28 days. Given
the loss of statistical significance upon further regression
analysis and the benefit seen only after 28 days, the small
difference in 90-day mortality that initially emerged in the
subgroup analysis of patients with septic shock is very
likely due to chance.
Caution in interpreting effect sizes
The ALBIOS trial suggested that albumin was associated
with ‘small but significant hemodynamic advantages’,
specifically a lower heart rate and higher mean arterial
pressure [1]. In this analysis, statistical significance fails to
represent clinical significance. The statistically significant
differences in heart rate and mean arterial pressure ranged
from 2 to 5 beats/minute and from 1 to 2 mm Hg,
respectively. The lack of clinical significance is supported
by the fact that meaningful differences failed to emerge at
any time point in the central venous oxygen saturation
and lactate values between the two groups. Similar claims
of superiority are made for albumin with regard to net
fluid balance. However, these differences were only statis-
tically significant and marginally clinically significant on
days 2 to 4, with the difference only favoring albumin
by ≤300 ml/day.
Caution in evaluating open-label endpoints at risk
for bias
In the subgroup of patients with septic shock receiving
vasopressors and/or inotropes at enrollment, a tertiary
analysis suggested that use of albumin was associated with
fewer days of vasopressor or inotrope support (median
3 days (interquartile range 1 to 6) vs. 4 days (interquartile
range 2 to 7), P = 0.007). Of note, the ALBIOS trial was an
open-label study, which may have biased the vasopressor
titrations. Additionally, analyzing hours as opposed to
days of vasopressor duration may have clarified the true
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effect size. Nevertheless, vasopressor agents are not be-
nign medications and a reduction in their use could be of
benefit.
Implications of the ALBIOS trial
Aside from the benefit of potentially reducing vasopres-
sor duration, the ALBIOS trial was largely a negative
study for albumin in terms of improving outcomes
compared with fluid alone. However, one must critically
evaluate the data and published analysis or risk misinter-
preting the study as favorable for albumin based on
interpretations of the subgroup analysis and effect sizes.
A multicenter French study investigating albumin in
septic shock is expected to shed additional light on the
relationship between albumin and vasopressor use [4].
Considering all available data, albumin should be
considered a safe alternative to crystalloids. The cost-
effectiveness of its use, however, remains a valid concern.
Volume for volume, albumin is roughly 30 times more
expensive than crystalloids [5]. Without any demonstrated
superiority in clinical outcomes, it is difficult to justify
extensive and unrestricted use of albumin at this time for
resuscitation of patients with severe sepsis or septic shock.
Abbreviation
ALBIOS: Albumin Italian Outcome Sepsis.
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